257 related articles for article (PubMed ID: 38177669)
1. Structural basis for partial agonism in 5-HT
Felt K; Stauffer M; Salas-Estrada L; Guzzo PR; Xie D; Huang J; Filizola M; Chakrapani S
Nat Struct Mol Biol; 2024 Apr; 31(4):598-609. PubMed ID: 38177669
[TBL] [Abstract][Full Text] [Related]
2. High-resolution structures of multiple 5-HT
Basak S; Kumar A; Ramsey S; Gibbs E; Kapoor A; Filizola M; Chakrapani S
Elife; 2020 Oct; 9():. PubMed ID: 33063666
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of setron-mediated inhibition of full-length 5-HT
Basak S; Gicheru Y; Kapoor A; Mayer ML; Filizola M; Chakrapani S
Nat Commun; 2019 Jul; 10(1):3225. PubMed ID: 31324772
[TBL] [Abstract][Full Text] [Related]
4. CSTI-300 (SMP-100); a Novel 5-HT
Roberts A; Grafton G; Powell AD; Brock K; Chen C; Xie D; Huang J; Liu S; Cooper AJ; Brady CA; Qureshi O; Stamataki Z; Manning DD; Moore NA; Sargent BJ; Guzzo PR; Barnes NM
J Pharmacol Exp Ther; 2020 Apr; 373(1):122-134. PubMed ID: 32102919
[TBL] [Abstract][Full Text] [Related]
5. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.
Gasiorek A; Trattnig SM; Ahring PK; Kristiansen U; Frølund B; Frederiksen K; Jensen AA
Biochem Pharmacol; 2016 Jun; 110-111():92-108. PubMed ID: 27086281
[TBL] [Abstract][Full Text] [Related]
6. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
7. Conformational Changes in the 5-HT
Munro L; Ladefoged LK; Padmanathan V; Andersen S; Schiøtt B; Kristensen AS
Mol Pharmacol; 2019 Dec; 96(6):720-734. PubMed ID: 31582575
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches to the treatment of nausea and vomiting.
Ladabaum U; Hasler WL
Dig Dis; 1999; 17(3):125-32. PubMed ID: 10697661
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of effects of electroacupuncture at "Tianshu" (ST25) and "Dachangshu" (BL25) on intestinal sensitivity and expression of muscarinic M
Ji MX; Guo MW; Gao YS; Lan Y; Wang S; Wang YF; Qin Y; Zhang HL; Ren XX
Zhen Ci Yan Jiu; 2019 Apr; 44(4):264-9. PubMed ID: 31056879
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
Spiller R
Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():25-31. PubMed ID: 17620085
[TBL] [Abstract][Full Text] [Related]
11. Unraveling mechanisms underlying partial agonism in 5-HT3A receptors.
Corradi J; Bouzat C
J Neurosci; 2014 Dec; 34(50):16865-76. PubMed ID: 25505338
[TBL] [Abstract][Full Text] [Related]
12. A re-consideration of neural/receptor mechanisms in chemotherapy-induced nausea and vomiting: current scenario and future perspective.
Ullah I; Ayaz M
Pharmacol Rep; 2023 Oct; 75(5):1126-1137. PubMed ID: 37584820
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.
Kurzwelly D; Barann M; Kostanian A; Combrink S; Bönisch H; Göthert M; Brüss M
Pharmacogenetics; 2004 Mar; 14(3):165-72. PubMed ID: 15167704
[TBL] [Abstract][Full Text] [Related]
14. [Migraine and irritable bowel syndrome].
Mulak A; Paradowski L
Neurol Neurochir Pol; 2005; 39(4 Suppl 1):S55-60. PubMed ID: 16419571
[TBL] [Abstract][Full Text] [Related]
15. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
[TBL] [Abstract][Full Text] [Related]
16. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
17. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
Durand JP; Madelaine I; Scotté F
Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists.
Kaiser R; Tremblay PB; Sezer O; Possinger K; Roots I; Brockmöller J
Pharmacogenetics; 2004 May; 14(5):271-8. PubMed ID: 15115912
[TBL] [Abstract][Full Text] [Related]
19. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.
de Boer-Dennert M; de Wit R; Schmitz PI; Djontono J; v Beurden V; Stoter G; Verweij J
Br J Cancer; 1997; 76(8):1055-61. PubMed ID: 9376266
[TBL] [Abstract][Full Text] [Related]
20. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Tan M
Expert Opin Pharmacother; 2003 Sep; 4(9):1563-71. PubMed ID: 12943486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
